We previously reported that, at median follow-ups of 34 and 68 months, enzalutamide improved overall survival (OS) compared with a first-generation non-steroidal anti-androgen (NSAA) when added to testosterone suppression for metastatic hormone-sensitive prostate cancer (mHSPC). We now report longer-term outcomes, with a focus on adverse events and causes of death.
Keywords: Enzalutamide, androgen deprivation therapy, hormone-sensitive prostate cancer, non-steroidal anti-androgen, randomised controlled trial
Annals of oncology : official journal of the European Society for Medical Oncology
Journal Article
English
42607762
Guideline Central and select third party use “cookies” on this website to enhance the user experience.
This technology helps us gather statistical and analytical information to optimize the relevant content for you.
The user also has the option to opt-out which may have an effect on the browsing experience.